Director Of Software Security CadenceDirector Of Software SecuritySan Jose, CA$164,500–$305,500 / yearCadence InfoSec is seeking a Director of Software Security to lead the strategy, architecture, and execution of secure software development practices across the enterprise. This role will drive DevSecOps transformation, ensure compliance with regulatory frameworks (including CMMC), and embed security throughout the software lifecycle (SDLC).
NewDirector of Software engineering JobotDirector of Software engineeringMenlo Park, CA$250,000–$350,000 / yearInformation collected and processed as part of your Jobot candidate profile, and any job applications, resumes, or other information you choose to submit is subject to Jobot's Privacy Policy, as well as the Jobot California Worker Privacy Notice and Jobot Notice Regarding Automated Employment Decision Tools which are available at jobot.com/legal. By applying for this job, you agree to receive calls, AI-generated calls, text messages, or emails from Jobot, and/or its agents and contracted partners.
Director, Connectors Veeam Software Group GmbHDirector, ConnectorsSan Jose, CA$366,300–$680,200 / yearDeliver high-scale, resilient scanning by guiding distributed workers (Go and/or Python) that scan very large environments across hybrid cloud without disrupting source systems, including strong auth support (OAuth, mTLS, JWT) and self-healing behavior for rate limits and failures. Own the connector framework by setting the architecture and roadmap for a scalable, flexible platform that supports integrations such as Snowflake, Salesforce, Databricks, Microsoft 365, and vector databases like Pinecone and Milvus.
Server IO Specialist. Sr. Director of Technology Qualcomm IncServer IO Specialist. Sr. Director of TechnologySanta Clara, CA$284,900–$427,300 / yearMinimum Qualifications: Bachelor''s degree in Electrical Engineering, Computer Engineering, Computer Science, or related field and 10+ years of Hardware Engineering, Software Engineering, Electrical Engineering, Systems Engineering, or related work experience. Master''s degree in Electrical Engineering, Computer Engineering, Computer Science, or related field and 9+ years of Hardware Engineering, Software Engineering, Electrical Engineering, Systems Engineering, or related work experience.
Director, Regulatory Affairs (US Filing Lead) Revolution MedicinesDirector, Regulatory Affairs (US Filing Lead)Redwood City, California$211,000–$264,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Degree in life sciences, pharmacy, medicine, or related fields with a minimum of 12 years in the pharmaceutical/biotech industry or relevant work experience and a minimum of 8 years in Regulatory Affairs including a regulatory strategy role.
Associate Creative Director, Design Gen Digital IncAssociate Creative Director, DesignMountain View, CAOur combined heritage is rooted in financial empowerment and cyber safety for the first digital generations, and today we deliver award-winning cybersecurity, online privacy, identity protection and financial wellness solutions to nearly 500 million users in more than 150 countries. You'll partner closely with creative leadership, brand, strategy, product, marketing, and cross-functional teams to bring ideas to life across a global portfolio of world-renowned brands.
Director, Quality & Regulatory Affairs AbbottDirector, Quality & Regulatory AffairsLivermore, California12+ years of progressive experience in healthcare regulatory compliance, accreditation, licensing, quality systems, or related disciplines, including direct people leadership experience with demonstrated success developing and managing high-performing teams. Acelis Connected Health (ACH) operates accredited Durable Medical Equipment (DME) and Independent Diagnostic Testing Facility (IDTF) businesses across all 50 states, supporting more than 80,000 patients through innovative connected healthcare solutions.
Director, Software Engineering (Cortex Platform) Palo Alto Networks IncDirector, Software Engineering (Cortex Platform)CA$232,000–$320,750 / yearStrong expertise in designing and managing distributed, high-throughput database architectures capable of supporting real-time data ingestion and heavy read/write workloads at enterprise scale. For candidates who receive an offer at the posted level, the starting base salary (for non-sales roles) or base salary + commission target (for sales/com-missioned roles) is expected to be the annual range listed below.
Senior Director, People Business Partner - Idira Palo Alto Networks IncSenior Director, People Business Partner - IdiraCA$240,000–$331,250 / yearIn this leadership role, you will serve as a strategic thought partner to senior leaders, bringing deep expertise in organizational design, talent strategy, and workforce planning to anticipate enterprise challenges and execute high-impact HR programs. You will shape and drive the overarching people strategies across our Idira leadership team and key cross-functional areas, translating business goals into bold, data-backed people strategies while cultivating an inclusive environment that attracts and retains world-class talent.
NewSenior Director, Global Design and Construction Data Analytics Equinix IncSenior Director, Global Design and Construction Data AnalyticsRedwood City, CAThe targeted pay range for this position in the following location is / locations are: United States - Dallas Infomart Office DAI: 200,000 - 300,000 USD / Annual. Dynamic, forward-thinking leader with a bias for action, rapid experimentation, and ability to break down complex problems and deliver novel solutions to address them.
Senior Director, Global Design And Construction Data Analytics Equinix, Inc.Senior Director, Global Design And Construction Data AnalyticsRedwood City, CAThe targeted pay range for this position in the following location is / locations are: United States- Dallas Infomart Office DAI: 200,000 - 300,000 USD / Annual. Dynamic, forward-thinking leader with a bias for action, rapid experimentation, and ability to break down complex problems and deliver novel solutions to address them.
Director, Software Engineering SnapLogic IncDirector, Software EngineeringSan Mateo, CAAI Leadership & Engineering Productivity: You champion the adoption of AI throughout the Software Development Life Cycle (SDLC), driving the use of AI as a force multiplier to enhance engineering excellence, accelerate software delivery, and improve product quality. Additionally, you will drive people management by delegating technical ownership over SME areas, establishing leaders, providing constructive feedback, advocating for career growth, conducting regular bi-weekly 1-on-1s, and resolving any internal conflicts.
Executive Director, Global Patient Safety Quality And Compliance - Pharmacovigilance Revolution Medicines, Inc.Executive Director, Global Patient Safety Quality And Compliance - PharmacovigilanceRedwood City, CA$265,000–$331,000 / yearThe responsibilities of this role include oversight of the PV-QMS, PV training strategy, PV controlled documentation, inspection and audit management, ensuring inspection readiness, Corrective Action Preventive Action (CAPA) management, Quality Assurance (QA), and maintenance of Good Clinical Practice (GCP), and Good Pharmacovigilance Practices (GVP) in partnership with GPS management, QA, and staff. This critical role will require strategic thinking, expert knowledge of global PV regulations (i.e. GCP, GVP), the ability to influence and communicate ideas effectively, results orientation, collaboration with cross-functional teams, technical expertise, and vendor management skills to ensure compliance with regulatory requirements to safeguard patient well-being.
Senior Medical Director - Late Stage Revolution Medicines, Inc.Senior Medical Director - Late StageRedwood City, CA$346,000–$397,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Senior Director, US Compliance Revolution Medicines, Inc.Senior Director, US ComplianceRedwood City, CA$244,000–$305,000 / yearAreas of focus include: Serve as the strategic compliance advisor to Commercial, Medical Affairs, Market Access, Patient Services, and other field-facing functions by proactively identifying compliance risks, enabling compliant business solutions, and embedding compliance into key business decisions throughout commercialization and product launch. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Clinical Operations Revolution Medicines, Inc.Associate Director, Clinical OperationsRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Proven experience working with investigators, external experts and regulatory agencies and oversight of Contract Research Organizations and third-party vendors including realigning with CRO partners when deliverables are at risk, negotiating solutions and leading After Action Reviews to share lessons learned.
Director, Externally Sponsored Research Revolution Medicines, Inc.Director, Externally Sponsored ResearchRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: The Director, Externally Sponsored Research (ESR) (including investigator sponsored trials and collaborative research) will lead the strategy, oversight, and execution of Revolution Medicines' ESR processes within one of our disease areas.
Senior Director, Clinical Operations, Global Clinical Vendor Contracts & Budgets Revolution Medicines, Inc.Senior Director, Clinical Operations, Global Clinical Vendor Contracts & BudgetsRedwood City, CA$244,000–$305,000 / yearThe leadership role ensures alignment with strategic objectives, regulatory requirements, and study timelines as well as bringing deep expertise in managing complex trials, contract negotiations, budget development, risk management, and cross-functional collaboration to contribute to the highest quality with on time delivery of RevMed's clinical studies. A member of the Clinical Operations team Leading the Contracts and Outsourcing for all vendor relationships within Clinical Development, the Sr Director Global Vendor Outsourcing will lead the strategic identification and selection process with the teams for vendors and CROs, including scope specifications for clinical programs, and will work closely with the Sr.
Executive Director, Early Clinical Development Revolution Medicines, Inc.Executive Director, Early Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Clinical Supply Chain Revolution Medicines, Inc.Executive Director, Clinical Supply ChainRedwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Senior Director, Molecule Global Regulatory Lead Revolution Medicines, Inc.Senior Director, Molecule Global Regulatory LeadRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provide strategic oversight for the planning and execution of major regulatory submissions, including INDs, CTAs, amendments, expedited designation requests, marketing applications, and lifecycle submissions.
Director, Clinical Data Management Revolution Medicines, Inc.Director, Clinical Data ManagementRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Associate Director, Environmental Health And Safety Revolution Medicines, Inc.Associate Director, Environmental Health And SafetyRedwood City, CA$186,000–$233,000 / yearManage occupational health program activities in partnership with internal stakeholders and external providers, including workplace injury and illness investigation and tracking, animal allergen questionnaire administration and follow-up, hepatitis B vaccination program support, ergonomics program coordination and continuous improvement, and maintenance of related documentation, metrics, and compliance records. Support Facilities Safety Programs through cross-functional collaboration and subject matter expertise, ensuring effective implementation of programs such as electrical safety, lockout/tagout, fall protection, confined space, heat illness prevention, and hot work, while maintaining clear role distinction from program ownership.
Executive Director, GCP QA (Good Clinical Practice, Quality Assurance) Revolution Medicines, Inc.Executive Director, GCP QA (Good Clinical Practice, Quality Assurance)Redwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Minimum of 15 years of experience in the pharmaceutical or biotechnology industry, including at least 10 years in GCP QA or clinical quality leadership roles, with demonstrated experience leading and hosting regulatory inspections (e.g., FDA BIMO, EMA, MHRA, PMDA).
Medical Director, Early-Stage Clinical Development Revolution Medicines, Inc.Medical Director, Early-Stage Clinical DevelopmentRedwood City, CA$295,000–$339,000 / yearHas demonstrated collaborative behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Clinical Data Management Revolution Medicines, Inc.Associate Director, Clinical Data ManagementRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Associate Director, Precision Medicine & Companion Diagnostics Revolution Medicines, Inc.Associate Director, Precision Medicine & Companion DiagnosticsRedwood City, CA$186,000–$233,000 / yearThe Opportunity: Revolution Medicines is offering a highly visible opportunity for talented and motivated individual to join our Precision Medicine Companion Diagnostics team as an Associate Director, Companion Diagnostics within the Translational Medicine function, which supports CDx development across RevMed portfolio. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Director, Regulatory Affairs (US Filing Lead) Revolution Medicines, Inc.Director, Regulatory Affairs (US Filing Lead)Redwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Required Skills, Experience and Education: Degree in life sciences, pharmacy, medicine, or related fields with a minimum of 12 years in the pharmaceutical/biotech industry or relevant work experience and a minimum of 8 years in Regulatory Affairs including a regulatory strategy role.
Director, Regulatory Affairs - US Filing Lead Revolution Medicines, Inc.Director, Regulatory Affairs - US Filing LeadRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Required Skills, Experience and Education: Degree in life sciences, pharmacy, medicine, or related fields with a minimum of 12 years in the pharmaceutical/biotech industry or relevant work experience and a minimum of 8 years in Regulatory Affairs including a regulatory strategy role.
Director, Stability Management, Analytical Development And Quality Control Revolution Medicines, Inc.Director, Stability Management, Analytical Development And Quality ControlRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Collaborate cross-functionally with teams in drug substance, drug product, supply chain, quality, regulatory, sourcing and other related team to ensure alignment of stability design and achieve stability study objectives.
Senior Director, Clinical Biomarker Operations Revolution Medicines, Inc.Senior Director, Clinical Biomarker OperationsRedwood City, CA$244,000–$305,000 / yearThe Opportunity: Revolution Medicines is seeking a strategic and experienced leader to serve as Senior Director, Clinical Biomarker Operations, responsible for leading the operational execution of biomarker and companion diagnostic (CDx) strategies across early- and late-stage clinical development programs. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, CMC Regulatory Revolution Medicines, Inc.Associate Director, CMC RegulatoryRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: As part of our expanding organization, we seek a strategic and hands-on Associate Director, CMC Regulatory who will be responsible for executing CMC regulatory strategies to support clinical development, marketing authorizations, and lifecycle management of RevMed's pipeline compounds/products.
Director, Portfolio Omnichannel (Lung Hcp) Revolution Medicines, Inc.Director, Portfolio Omnichannel (Lung Hcp)Redwood City, CA$211,000–$264,000 / yearThe Director, Portfolio Omnichannel Strategy & Operations (Oncology Lung HCP) is a highly collaborative leader focused on both strategy & execution and is responsible for partnering with Brand & Commercial function Leads in translating oncology brand strategies into high-impact, compliant, and innovative customer engagement experiences. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Computational Systems Biology Revolution Medicines, Inc.Executive Director, Computational Systems BiologyRedwood City, CA$265,000–$331,000 / yearThe individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Director, Data Engineering & Architecture (Remote) Ceribell, IncDirector, Data Engineering & Architecture (Remote)Sunnyvale, CARemote$210,000–$272,000 / yearThe Ceribell System is a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting, and is being used in hundreds of community hospitals, large academic facilities and major IDN's across the country. This role bears the primary responsibility for facilitating communication and execution across Commercial, Engineering, Financial, Infrastructure, and Security teams, ensuring that our systems drive organizational efficiency, effectiveness, and flexibility.
Senior Medical Director, Early-Stage Clinical Development Revolution Medicines, Inc.Senior Medical Director, Early-Stage Clinical DevelopmentRedwood City, CA$346,000–$397,000 / yearHas demonstrated collaborative behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Regional Director, Independent Advisors (Remote/In-Territory Eligible) - Northern California Dimensional Fund AdvisorsRegional Director, Independent Advisors (Remote/In-Territory Eligible) - Northern CaliforniaCARemoteJust as important, the Regional Director must have a strong business development and client service orientation and understand the issues and challenges Advisors face in building a client-centric, fee-based business. • Present Dimensional Fund Advisors investment capabilities, investment theory and performance to Financial Advisors, branch offices, company conferences and industry functions.
Executive Director, Clinical Development Revolution Medicines, Inc.Executive Director, Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Dental Hygiene Program Director San Joaquin Valley College, Inc.Dental Hygiene Program DirectorSan Jose, CA$105,000–$120,000 / yearPart timeManagement Excellence - Includes staff in planning, decision-making, facilitating and process improvement; takes responsibility for employee’s activities; is accessible to staff; provides regular performance feedback; develops employee’s skills and encourages growth; solicits and applies employee and student feedback; fosters quality focus in others; improves processes; continually works to improve supervisory skills. Training and Development – Ensures staff members get receive orientation, training and development opportunities to maximize success in their assignments; views training and development as an investment in employees and uses mentoring, cross-functional assignments, job rotation or other on-the-job learning opportunities to enhance the depth and breadth of skills and experience; encourages self-development opportunities.
Associate Director, Clinical Biomarker Development Revolution Medicines, Inc.Associate Director, Clinical Biomarker DevelopmentRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: The Associate Director in Clinical Biomarker Development team, within Translational Medicine will play a key role in the design, execution, and interpretation of clinical biomarker strategies across Revolution Medicine's oncology pipeline.
Senior Director, Global Patient Safety Quality And Compliance Revolution Medicines, Inc.Senior Director, Global Patient Safety Quality And ComplianceRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Senior Director will provide broad oversight across case processing, vendor governance, safety systems and processes, aggregate reporting operations, partner interfaces, and operational readiness while developing leaders and serving as a key advisor to cross-functional stakeholders.
Senior Director, Global Patient Safety Operations Revolution Medicines, Inc.Senior Director, Global Patient Safety OperationsRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Senior Director will provide broad oversight across case processing, vendor governance, safety systems and processes, aggregate reporting operations, partner interfaces, and operational readiness while developing leaders and serving as a key advisor to cross-functional stakeholders.
Associate Director, Global Regulatory Affairs Project Management Revolution Medicines, Inc.Associate Director, Global Regulatory Affairs Project ManagementRedwood City, CA$186,000–$233,000 / yearDrive the operational planning, coordination, and tracking of new drug marketing application submission activities across cross-functional Filing Teams (including Regulatory, Medical Writing, Nonclinical, Clinical, Safety, Biostatistics, CMC / Pharmaceutical Development and Manufacturing, etc. and external consultants), supporting the Global Filing Lead's strategic vision. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Sr. Director, Product Marketing Manager (SASE) Palo Alto Networks IncSr. Director, Product Marketing Manager (SASE)CA$252,000–$346,500 / yearYou will oversee the marketing strategy for our comprehensive suite of Cloud-Delivered Security Services (CDSS)-including Advanced Threat Prevention, URL Filtering, DNS Security, and IoT Security-positioning them as the native, AI-powered security engine that gives our SASE platform its unparalleled competitive edge. This role will set the marketing direction and own the messaging architecture for our end-to-end SASE business, seamlessly integrating our core networking capabilities with our comprehensive suite of Cloud-Delivered Security Services (CDSS) to deliver an unmatched, unified security edge solution.
Senior Medical Director, Early-Stage Clinical Development Revolution MedicinesSenior Medical Director, Early-Stage Clinical DevelopmentRedwood City, CaliforniaHas demonstrated collaborative behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Computational Systems Biology Revolution MedicinesExecutive Director, Computational Systems BiologyRedwood City, CaliforniaThe individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Clinical Development Revolution Medicines IncExecutive Director, Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Director, Product Management, AI Support Hewlett Packard EnterpriseDirector, Product Management, AI SupportCupertino, CaliforniaPartner closely with engineering, data science, UX, support operations, and customer success teams to identify customer pain points, define product requirements, and deliver scalable AI solutions that improve customer satisfaction, accelerate resolution times, increase support productivity, and reduce operational costs. Please note that Hewlett Packard Enterprise (HPE), its direct and indirect subsidiaries and affiliated companies, and its authorized recruitment agencies/vendors will never charge a candidate a registration fee, hiring fee, or any other fee in connection with its recruitment and hiring process.
Senior Director, Global Patient Safety Quality and Compliance Revolution MedicinesSenior Director, Global Patient Safety Quality and ComplianceRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Senior Director will provide broad oversight across case processing, vendor governance, safety systems and processes, aggregate reporting operations, partner interfaces, and operational readiness while developing leaders and serving as a key advisor to cross-functional stakeholders.
Executive Director, Clinical Development Revolution MedicinesExecutive Director, Clinical DevelopmentRedwood City, CaliforniaHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.